Loading...

SPRO SPERO THERAPEUTICS INC Legal Disputes 8-K Filing

SPR

SPR

SPERO THERAPEUTICS INC

(SPRO)

2025 8-K

Quarterly Results

Product Expansion

Financial Statements

Earnings Report

SEC Investigation

Q3 Earnings Report

Workforce Reduction

Investor Update

Earnings Reports

Amendment to Stock Incentiv...

Annual Meeting Announcement

Financial Results Announcement

Departure of Directors or C...

Presentation Update

Financial Condition

Clinical Trial Announcement

Earnings Reports

Appointment of Esther Rajav...

Amendment to Filing

Stock Incentive Plan Amendment

Earnings Reports

FDA Agreement for Phase 3 C...

Earnings Report

Financial Results Announcement

Appointment of Chief Operat...

Financial Condition

External Links:

Spero Therapeutics reported having approximately $52.9 million in cash as of December 31, 2024, and is under SEC investigation regarding past disclosures, leading to interim leadership changes with Esther Rajavelu appointed as Interim CEO.

AI Assistant

SPERO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.